|
Author: Shima Y, Kuwahara Y, Murota H, Kitaba S, et al Date Published: September-2010 Source: Rheumatology (Oxford)
Objective. SSc is an autoimmune disease characterized by fibrosis of the skin and internal organs. Although the aetiology remains uncertain, many reports have suggested that IL-6 is involved in SSc pathogenesis. Tocilizumab, an anti-IL-6 receptor antibody, is an anti-arthritis medicine that works through the blockade of IL-6 functions.
|